UC
Subcutaneous Infliximab Found Effective With or Without an Immunosuppressant
Patients who achieved a clinical response to subcutaneous infliximab showed no meaningful differences in outcomes ...
APRIL 28, 2025
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
FDA Approves Guselkumab for UC
The FDA has approved Tremfya for patients with moderately to severely active ulcerative colitis.
SEPTEMBER 12, 2024
2 Exciting New FDA Approvals For Ulcerative Colitis Treatment
In this month’s The Regueiro Report, I’d like to highlight two exciting FDA approvals for moderately to ...
APRIL 1, 2024
FDA Approves Subcutaneous Vedolizumab for Moderate to Severe UC
The FDA has approved a subcutaneous version of Entyvio for maintenance therapy in adults with moderate to severe ...
OCTOBER 5, 2023
In UC, Tofacitinib and Ustekinumab Perform Similarly After Biologic Failure
In biologic-experienced patients with ulcerative colitis, tofacitinib and ustekinumab achieve about the same rate ...
MAY 17, 2023
FDA Approves Zeposia for Treatment of Ulcerative Colitis
The FDA has approved ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of adults with moderately to ...
JUNE 1, 2021
Ozanimod Met Phase 3 Trial End Points for Ulcerative Colitis
Ozanimod, an oral therapy with a unique targeted mechanism of action, was effective for the control of ulcerative ...
MARCH 16, 2021
